The pillars of CKD treatment in persons with T2D, RAS inhibition, SGLT2 inhibitors, finerenone, and GLP‐1 RAs, are built on the foundation of lifestyle modifications that include cessation of smoking, BP control, lipid management, physical activity, maintenance of a healthy weight, and a diet low in sodium. The gene discussed is SLC5A2; the disease is chronic kidney disease.